Larry Ramer

Larry Ramer

InvestorPlace Contributor

Larry Ramer has more than 15 years of experience in business journalism. He has worked for Globes, Israel’s most widely read business newspaper, as well as The Jerusalem Post and theflyonthewall.

Mr. Ramer’s expansive knowledge of politics enables him to provide valuable insights into how politics can affect stocks. He also focuses on contrary investing and specializes in the renewable energy and consumer discretionary sectors.

Among his highly successful, contrarian picks have been Super Micro Computer, Intel, and MGM Resorts.

You can reach him on StockTwits at @larryramer and learn more about his stock-picking record at his TipRanks profile.

Recent Articles

Buy Good News Gilead Stock Before Other Investors Catch On

By Larry Ramer, InvestorPlace Contributor

Positive signs continue to mount for remdesivir, yet the market continues to have mixed feelings about GILD stock.

Sell Salesforce Stock Now in Favor of Amazon or Microsoft

By Larry Ramer, InvestorPlace Contributor

Salesforce was struggling to grow its business even before the pandemic. Sell CRM stock and check out one of these bigger names instead.

Favorable Oil, Macro Trends Will Boost Exxon

By Larry Ramer, InvestorPlace Contributor

With lockdowns easing and a strong economic rebound likely in 2021, Exxon Mobil stock should benefit from a short- and long-term boost.

Why iBio Stock Could Soar 500% Above Its Current Levels

By Larry Ramer, InvestorPlace Contributor

IBIO stock is backed by promising technology in its efforts to make a coronavirus vaccine and a well-connected partner.

Gilead Stock Still Looks Poised to Prove the Bears Wrong

By Larry Ramer, InvestorPlace Contributor

With remdesivir poised to become a blockbuster drug for Gilead, GILD stock still looks poised to prove the bears wrong

Load More